Online First (2024)

Grand Rounds

Beyond Standard Endocrine Therapy: A New Adjuvant Treatment in High-Risk Early Breast Cancer

Barbara Dean, DMSc, PA-C, DFAAPA

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors with endocrine therapy have shown benefit in ER-positive, HER2-negative breast cancer in the metastatic setting. This article reviews a case study and rationale for the use of oral CDK...

July 22, 2024

Review Article

Diversity, Equity, and Inclusion in Multiple Myeloma: A Call to Action

Rebecca Lu, MSN, FNP-C,Joseph D. Tariman, PhD, MBA, ANP-BC, FAAN,Donna Catamero, ANP-BC, OCN, CCRC,et al.

Although there have been rapid advancements in multiple myeloma therapy, pervasive racial and social inequities prevent uniform benefit across all patient populations. This article identifies inequities in race, age, socioeconomic statu...

July 22, 2024

Translating Research Into Practice

A Real-World Evidence Primer for Advanced Practice Providers: Integrating P-Reality X Into Shared Decision-Making for People With HR+/HER2− Metastatic Breast Cancer

Sarah Donahue, MPH, NP,Joanne C. Ryan, PhD, RN,Kimberly Podsada, MSN, NP-C et al.

This article provides an overview of the fundamental aspects of real-world data (RWD) studies and what is required to conduct a robust RWD study.

July 22, 2024

Research and Scholarship

Evaluating the User-Perceived Benefit of a Virtual Lung Cancer Patient Education and Support Community: LVNG With Lung Cancer

Mona L. Martin, RN, MPA,Kristin Bucklen, BS, MBA,Lise J. Hall, BA, MBA,et al.

A Facebook community for people living with lung cancer and their support partners, LVNG With Lung Cancer, led to behavioral change in many members, such as asking their care team more questions. Patients and their support partners were ...

July 21, 2024

Research and Scholarship

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium

Elizabeth Koselke, PharmD, BCOP,Lisa C. Kaspin-Powell, PhD,Shannon Hough, PharmD, BCOP,et al.

The US Oncology Network recently implemented a clinical pharmacist (ClinReview) initiative to provide remote clinical services to screen patients for enrollment onto MYLUNG Protocol 2. This study aims to evaluate the effect of the remote...

July 21, 2024

Prescriber's Corner

Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib

Justin Arnall, PharmD, BCOP,Lindsey Lyle, MS, PA-C,Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP et al.

This article reviews the pharmacology, efficacy, safety, dosing, administration, and implications for advanced practitioners of newer JAK inhibitors (fedratinib, pacritinib, and momelotinib) in the treatment of myelofibrosis.

May 22, 2024

Review Article

How Can Oncology Nurses and Advanced Practice Providers Reduce the Burden of Chemotherapy-Induced Febrile Neutropenia in the US?

Kristi Kay Orbaugh, MSN, NP, AOCNP,Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP,Lisa Kennedy Sheldon, PhD, APRN-BC, AOCNP®, FAAN et al.

This article provides a narrative review of US studies reporting on the burden of febrile neutropenia (FN), FN during COVID-19, adherence to guidelines for the use of prophylactic granulocyte colony-stimulating factors (G-CSFs), the inv...

May 22, 2024

Research and Scholarship

The Effect of Pelvic Floor Rehabilitation on Low Anterior Resection Syndrome After Colorectal Cancer Treatment

Shelby Jones, DNP, CCRN,Alison Edie, DNP,Emily Troop, DPT,et al.

The purpose of the quality improvement (QI) project was to assess the prevalence of low anterior resection syndrome (LARS) among the institute’s patient population and the effect of pelvic floor rehabilitation in treating and preventing ...

May 22, 2024

Review Article

Peripheral T-Cell Lymphoma, Not Otherwise Specified: Diagnosis and Therapeutic Approaches for the Advanced Practice Provider

Karla V. Ow, MSN, APRN, AOCNP,Ann Vo, MSN, APRN, FNP,Jonathan Cunningham, MPAS, PA-C et al.

This review aims to provide an up-to-date overview of the current therapeutic approaches for the subtype peripheral T-cell lymphoma, not otherwise specified.

January 03, 2024

Review Article

Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider

Gabriel Schwartz, MSN, FNP-BC, AOCNP,Julianne O. Darling, PharmD, BCOP

This review provides practical insights for advanced practice providers on the management of these common AEs associated with selective FGFR inhibitors in the real-world setting, focusing on pemigatinib and futibatinib.

February 14, 2024

Research and Scholarship

Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Project: Interventions for Improving Knowledge and Compliance With National Safety Standards

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP,Rita D’Aoust, PhD, MS, RN,,Deborah Baker, DNP, CRNP, NEA-BC, ,et al.

This quality improvement project evaluated provider and staff general knowledge on oral chemotherapy and national safety standards and the implementation and ease of use of an electronic medical record (EMR)-integrated chemotherapy docum...

January 05, 2024